Oncternal Therapeutics, Inc. (ONCT)
ONCT moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ONCT actually reacts to news — the realized, point-in-time move the market made, measured across 103 labeled events over the last three years with zero look-ahead.
ONCT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 29% | 52 |
| 30-min | 0.00% | 22% | 68 |
| 60-min | 0.00% | 25% | 71 |
| to close | 0.00% | 42% | 74 |
| Middle 50% of ONCT reactions | -1.92% to 0.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 103 |
Half of all Oncternal Therapeutics, Inc. news events land between -1.92% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ONCT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ONCT's baseline. Nothing else.
Recent ONCT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations | Press release | GlobeNewswire | — | — | |
| Form EFFECT Oncternal Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 15-12G Oncternal Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form POS AM Oncternal Therapeutics, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Oncternal Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 25 Oncternal Therapeutics, | SEC filing · Form 25 | SEC EDGAR | — | — | |
| Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC | Press release | GlobeNewswire | — | — | |
| Form 8-K Oncternal Therapeutics, For: Nov 22 | SEC filing · Form 8-K | SEC EDGAR | -4.16% | -14.46% | |
| Form 8-K Oncternal Therapeutics, For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | +0.00% | |
| Form 10-Q Oncternal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.54% | -19.88% | |
| Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | +0.47% | -13.65% | |
| Form 8-K Oncternal Therapeutics, For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -6.16% | -11.52% | |
| Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives | Press release | GlobeNewswire | +6.92% | +6.92% | |
| Form 10-Q Oncternal Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.18% | -8.54% | |
| Form 8-K Oncternal Therapeutics, For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -4.18% | -8.54% | |
| Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results | Press release | GlobeNewswire | -4.18% | -8.54% | |
| Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results | Press release | GlobeNewswire | +0.00% | -10.30% | |
| Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | +0.26% | -1.03% | |
| Oncternal Therapeutics to Present in JonesTrading Healthcare Summit | Press release | GlobeNewswire | — | +5.06% | |
| Form 8-K Oncternal Therapeutics, For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +1.87% | +0.11% | |
| Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | — | -1.07% | |
| Form 10-Q Oncternal Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -9.12% | |
| Form 8-K Oncternal Therapeutics, For: May 09 | SEC filing · Form 8-K | SEC EDGAR | — | -9.12% | |
| Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results | Press release | GlobeNewswire | — | -9.12% | |
| Form EFFECT Oncternal Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | +9.04% | |
| Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results | Press release | GlobeNewswire | — | — | |
| Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | — | +1.10% | |
| Form ARS Oncternal Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +0.95% | |
| Form DEF 14A Oncternal Therapeutics, For: Jun 20 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.95% | |
| Form DEFA14A Oncternal Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.95% | |
| Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | — | -2.27% | |
| Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer | Press release | GlobeNewswire | — | +3.08% | |
| Form S-3 Oncternal Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | — | +2.03% | |
| Form 10-K Oncternal Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +3.90% | |
| Form 8-K Oncternal Therapeutics, For: Mar 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.90% | |
| Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results | Press release | GlobeNewswire | +0.00% | +3.90% | |
| Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results | Press release | GlobeNewswire | +0.00% | +6.82% | |
| Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | — | -1.24% | |
| Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | — | -0.94% | |
| Form 8-K Oncternal Therapeutics, For: Jan 22 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | +31.13% | |
| Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | -5.29% | +0.14% | |
| Form 8-K Oncternal Therapeutics, For: Jan 03 | SEC filing · Form 8-K | SEC EDGAR | -5.29% | +0.14% | |
| Oncternal Therapeutics Announces Reverse Stock Split | Press release | GlobeNewswire | +2.63% | -21.96% | |
| Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.28% | +2.88% | |
| Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma | Press release | GlobeNewswire | -8.02% | +18.20% | |
| Form 10-Q Oncternal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.92% | +0.69% | |
| Form 8-K Oncternal Therapeutics, For: Nov 09 | SEC filing · Form 8-K | SEC EDGAR | +3.92% | +0.69% | |
| Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results | Press release | GlobeNewswire | +3.92% | +0.69% | |
| Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results | Press release | GlobeNewswire | +1.47% | +5.88% | |
| Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | -7.29% | -7.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ONCT section they belong to.
Where else ONCT is measured.
ONCT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oncternal Therapeutics, Inc.'s median reaction calculated?
Every labeled ONCT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 103 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 22% of ONCT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ONCT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.